Civica, Mayo Clinic and others sound off on FDA draft guidance to mitigate drug shortages
Several pharma groups are laying out the positives and negatives of new FDA draft guidance on how best to handle drug shortages.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
